BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ding J, Yang Y, Jiang L, Wu W, Shao Z. Predictive factors of pathologic complete response in HER2-positive and axillary lymph node positive breast cancer after neoadjuvant paclitaxel, carboplatin plus with trastuzumab. Oncotarget 2017;8:56626-34. [PMID: 28915617 DOI: 10.18632/oncotarget.17993] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Ning J, Fouad TM, Lin H, Sahin AA, Lucci A, Woodward WA, Krishnamurthy S, Tripathy D, Ueno NT, Shen Y. The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer. J Cancer 2019;10:2635-42. [PMID: 31258771 DOI: 10.7150/jca.32453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Xu Y, Lin Y, Wang Y, Zhou L, Xu S, Wu Y, Peng J, Zhang J, Yin W, Lu J. Association of Neo-Family History Score with pathological complete response, safety, and survival outcomes in patients with breast cancer receiving neoadjuvant platinum-based chemotherapy: An exploratory analysis of two prospective trials. EClinicalMedicine 2021;38:101031. [PMID: 34337367 DOI: 10.1016/j.eclinm.2021.101031] [Reference Citation Analysis]
3 Zhi W, Wang Y, Chang C, Wang F, Chen Y, Hu N, Zhu X, Xie L. US-guided Diffuse Optical Tomography: Clinicopathological Features Affect Total Hemoglobin Concentration in Breast Cancer. Transl Oncol 2018;11:845-51. [PMID: 29753185 DOI: 10.1016/j.tranon.2018.04.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
4 Zhao F, Huo X, Wang M, Liu Z, Zhao Y, Ren D, Xie Q, Liu Z, Li Z, Du F, Shen G, Zhao J. Comparing Biomarkers for Predicting Pathological Responses to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:731148. [PMID: 34778044 DOI: 10.3389/fonc.2021.731148] [Reference Citation Analysis]
5 Cerbelli B, Scagnoli S, Mezi S, De Luca A, Pisegna S, Amabile MI, Roberto M, Fortunato L, Costarelli L, Pernazza A, Strigari L, Della Rocca C, Marchetti P, d'Amati G, Botticelli A. Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer. Cancers (Basel) 2020;12:E2648. [PMID: 32947953 DOI: 10.3390/cancers12092648] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Rodriguez FC, Castillo-fernandez O, Lim-law M, Palacios CM, Montano L, Benitez S, Samudio J. Real-world data of subcutaneous trastuzumab and intravenous pertuzumab as neoadjuvant therapy for localized HER2+ breast cancer in Panama. Breast Cancer Management 2021;10:BMT. [DOI: 10.2217/bmt-2021-0003] [Reference Citation Analysis]
7 Xie Y, Wu S, Zhang Y, Li J, Mo M, Shao Z, Liu G. Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer. Front Oncol 2021;11:686591. [PMID: 34168999 DOI: 10.3389/fonc.2021.686591] [Reference Citation Analysis]
8 Namura M, Tsunoda H, Kobayashi D, Enokido K, Yoshida A, Watanabe T, Suzuki K, Nakamura S, Yamauchi H, Hayashi N. The Loss of Lymph Node Metastases After Neoadjuvant Chemotherapy in Patients With Cytology-proven Axillary Node-positive Primary Breast Cancer. Clin Breast Cancer 2019;19:278-85. [PMID: 30975473 DOI: 10.1016/j.clbc.2019.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]